NasdaqGS:RGNX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease.


Snowflake Analysis

Excellent balance sheet and fair value.


Similar Companies

Share Price & News

How has REGENXBIO's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RGNX has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.4%

RGNX

0.4%

US Biotechs

2.3%

US Market


1 Year Return

-21.7%

RGNX

28.5%

US Biotechs

6.7%

US Market

Return vs Industry: RGNX underperformed the US Biotechs industry which returned 28.5% over the past year.

Return vs Market: RGNX underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

RGNXIndustryMarket
7 Day-2.4%0.4%2.3%
30 Day5.8%10.8%7.4%
90 Day12.2%24.0%17.9%
1 Year-21.7%-21.7%29.8%28.5%9.0%6.7%
3 Year87.9%87.9%31.7%27.4%36.6%27.7%
5 Yearn/a-5.3%-10.6%64.2%46.1%

Price Volatility Vs. Market

How volatile is REGENXBIO's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is REGENXBIO undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: RGNX ($37.2) is trading below our estimate of fair value ($85.76)

Significantly Below Fair Value: RGNX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: RGNX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: RGNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RGNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RGNX is good value based on its PB Ratio (3.3x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is REGENXBIO forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

6.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RGNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RGNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RGNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RGNX's revenue (27% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: RGNX's revenue (27% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RGNX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has REGENXBIO performed over the past 5 years?

-2.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RGNX is currently unprofitable.

Growing Profit Margin: RGNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RGNX is unprofitable, and losses have increased over the past 5 years at a rate of -2.9% per year.

Accelerating Growth: Unable to compare RGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: RGNX has a negative Return on Equity (-24.41%), as it is currently unprofitable.


Next Steps

Financial Health

How is REGENXBIO's financial position?


Financial Position Analysis

Short Term Liabilities: RGNX's short term assets ($338.2M) exceed its short term liabilities ($31.8M).

Long Term Liabilities: RGNX's short term assets ($338.2M) exceed its long term liabilities ($12.0M).


Debt to Equity History and Analysis

Debt Level: RGNX is debt free.

Reducing Debt: RGNX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RGNX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RGNX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is REGENXBIO current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RGNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RGNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RGNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Ken Mills (45yo)

11.33yrs

Tenure

US$6,147,269

Compensation

Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer and President at REGENXBIO Inc. since March 2009. Mr. Mills served as the Chief Financial Officer and Vice President of Busines ...


CEO Compensation Analysis

Compensation vs Market: Ken's total compensation ($USD6.15M) is above average for companies of similar size in the US market ($USD4.72M).

Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Kenneth Mills
CEO, President & Director11.33yrsUS$6.15m0.65% $9.0m
Vittal Vasista
Senior VP & CFO10.92yrsUS$2.18m0.56% $7.7m
Patrick Christmas
Senior VP & Chief Legal Officer3.92yrsUS$1.83m0.0069% $95.7k
Olivier Danos
Senior VP & Chief Scientific Officer3.33yrsUS$1.93m0.018% $253.0k
Stephen Pakola
Senior VP & Chief Medical Officer1.25yrsUS$4.01mno data
Curran Simpson
Senior VP and Chief Operations & Technology Officerno dataUS$1.90m0.011% $146.8k
Andrew Yost
Vice President of Corporate Development3.33yrsno datano data
Shiva Fritsch
Senior Vice President of Human Resources2.75yrsno datano data
Laura Coruzzi
Senior Vice President of Intellectual Property4.17yrsno datano data
Ram Palanki
Senior VP of Commercial Strategy & Operations1.92yrsno datano data

3.3yrs

Average Tenure

52yo

Average Age

Experienced Management: RGNX's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kenneth Mills
CEO, President & Director11.33yrsUS$6.15m0.65% $9.0m
David Stump
Independent Director4.75yrsUS$323.32kno data
Daniel Abdun-Nabi
Independent Director3.92yrsUS$318.32kno data
Argeris Karabelas
Lead Independent Directorno dataUS$317.82kno data
Inder Verma
Member of Scientific Advisorno datano datano data
Luke Beshar
Independent Director5.25yrsUS$333.32kno data
Allan Fox
Chairman of the Boardno dataUS$309.32k8.17% $113.2m
Judith Swain
Member of Scientific Advisorno datano datano data
Alexandra Glucksmann
Independent Director2.17yrsUS$312.83kno data
Daniel Tassé
Independent Director3.92yrsUS$315.32kno data

4.3yrs

Average Tenure

66.5yo

Average Age

Experienced Board: RGNX's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

REGENXBIO Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: REGENXBIO Inc.
  • Ticker: RGNX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.385b
  • Shares outstanding: 37.24m
  • Website: https://www.regenxbio.com

Number of Employees


Location

  • REGENXBIO Inc.
  • 9600 Blackwell Road
  • Suite 210
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RGNXNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDSep 2015
RB0DB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2015

Biography

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/12 00:01
End of Day Share Price2020/07/10 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.